Blocking viral entry represents a crucial battleground in pandemic preparedness, and new computational evidence suggests existing HIV medications could serve double duty against SARS-CoV-2. This cross-pathogen approach capitalizes on similar cellular invasion strategies shared between these seemingly different viruses.
Researchers examined three HIV-1 fusion inhibitors—CMK, Luteolin, and Naphthofluorescein—for their ability to interfere with Furin, a cellular protease essential for SARS-CoV-2 spike protein activation. Molecular docking studies revealed promising binding affinities: CMK achieved -7.4 kcal/mol, Luteolin reached -9.3 kcal/mol, and Naphthofluorescein demonstrated the strongest interaction at -10.7 kcal/mol. Extended 200-nanosecond molecular dynamics simulations confirmed stable compound-protein complexes, while pharmacokinetic analysis indicated favorable drug-like properties for all three candidates.
This drug repurposing strategy addresses a critical vulnerability in SARS-CoV-2's infection cycle. After the virus binds to ACE2 receptors, Furin protease cleaves the spike protein, enabling membrane fusion and cellular entry. By targeting this host-mediated step rather than viral components directly, such inhibitors could potentially resist viral mutations that often render spike-targeted therapies obsolete. The computational approach, while promising, represents early-stage research requiring wet-lab validation and clinical testing. However, the advantage of repurposing already-approved HIV drugs could significantly accelerate development timelines compared to novel therapeutic discovery. This work exemplifies how understanding shared molecular mechanisms across pathogens can reveal unexpected therapeutic opportunities, particularly valuable for future pandemic preparedness where rapid response capabilities prove essential.